Close Menu

NEW YORK (360Dx) – Amydis Diagnostics said that the National Institute on Aging had awarded it a Phase 2 SBIR grant of $1.8 million to fund R&D into an ophthalmic diagnostic probe for Alzheimer's disease.

The ability to identify amyloid-beta deposits helps in identifying patients at risk for Alzheimer's disease and enables enrollment of patients in clinical trials investigating disease modifying treatments, and may ultimately guide therapeutic intervention at an early stage, the firm said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.